We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Abbott (ABT) Gains But Lags Market: What You Should Know
Read MoreHide Full Article
Abbott (ABT - Free Report) closed at $117.57 in the latest trading session, marking a +0.49% move from the prior day. The stock lagged the S&P 500's daily gain of 1.71%.
Prior to today's trading, shares of the maker of infant formula, medical devices and drugs had lost 8.23% over the past month. This has lagged the Medical sector's loss of 5.62% and the S&P 500's loss of 2.25% in that time.
ABT will be looking to display strength as it nears its next earnings release, which is expected to be October 20, 2021. The company is expected to report EPS of $0.92, down 6.12% from the prior-year quarter. Our most recent consensus estimate is calling for quarterly revenue of $9.43 billion, up 6.52% from the year-ago period.
For the full year, our Zacks Consensus Estimates are projecting earnings of $4.42 per share and revenue of $39.88 billion, which would represent changes of +21.1% and +15.25%, respectively, from the prior year.
Investors should also note any recent changes to analyst estimates for ABT. These recent revisions tend to reflect the evolving nature of short-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.09% higher. ABT is currently sporting a Zacks Rank of #3 (Hold).
Valuation is also important, so investors should note that ABT has a Forward P/E ratio of 26.48 right now. For comparison, its industry has an average Forward P/E of 25.2, which means ABT is trading at a premium to the group.
We can also see that ABT currently has a PEG ratio of 2.23. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. Medical - Products stocks are, on average, holding a PEG ratio of 2.1 based on yesterday's closing prices.
The Medical - Products industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 174, which puts it in the bottom 32% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Abbott (ABT) Gains But Lags Market: What You Should Know
Abbott (ABT - Free Report) closed at $117.57 in the latest trading session, marking a +0.49% move from the prior day. The stock lagged the S&P 500's daily gain of 1.71%.
Prior to today's trading, shares of the maker of infant formula, medical devices and drugs had lost 8.23% over the past month. This has lagged the Medical sector's loss of 5.62% and the S&P 500's loss of 2.25% in that time.
ABT will be looking to display strength as it nears its next earnings release, which is expected to be October 20, 2021. The company is expected to report EPS of $0.92, down 6.12% from the prior-year quarter. Our most recent consensus estimate is calling for quarterly revenue of $9.43 billion, up 6.52% from the year-ago period.
For the full year, our Zacks Consensus Estimates are projecting earnings of $4.42 per share and revenue of $39.88 billion, which would represent changes of +21.1% and +15.25%, respectively, from the prior year.
Investors should also note any recent changes to analyst estimates for ABT. These recent revisions tend to reflect the evolving nature of short-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.09% higher. ABT is currently sporting a Zacks Rank of #3 (Hold).
Valuation is also important, so investors should note that ABT has a Forward P/E ratio of 26.48 right now. For comparison, its industry has an average Forward P/E of 25.2, which means ABT is trading at a premium to the group.
We can also see that ABT currently has a PEG ratio of 2.23. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. Medical - Products stocks are, on average, holding a PEG ratio of 2.1 based on yesterday's closing prices.
The Medical - Products industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 174, which puts it in the bottom 32% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.